1 |
Rauseo A, Pacilli A, Palena A, De Cosmo SA. Management of type 2 diabetes in geriatric patients. J Nephrol 2010;23(Suppl 15):S72-S79.
|
2 |
당뇨병 기초통계연구 Task Force Team 보고서. Diabetes 2007.
|
3 |
American Diabetes Association: Standards of medical care in diabetes: 2010. Diabetes Care 2010;33(Suppl 1):S11-S61.
DOI
|
4 |
Hazzard's Geriatric medicine and gerontology. 6th ed. New York: McGraw-Hill Companies, 2009.
|
5 |
대한당뇨병학회 노인당뇨병소연구회. 노인당뇨병. 제2판. 서울;고려의학, 2010.
|
6 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34): UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-865.
DOI
ScienceOn
|
7 |
Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49): UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-2012.
DOI
ScienceOn
|
8 |
Nattrass M, Lauritzen T. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of type 2 diabetes? Int J Obes Relat Metab Disord 2000;24(Suppl 3):S21-S31.
|
9 |
Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A diabetes outcome progression trial (ADOPT). Diabetes Care 2008;31:845-851.
DOI
ScienceOn
|
10 |
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471.
DOI
ScienceOn
|
11 |
Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125-2135.
DOI
ScienceOn
|
12 |
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705.
DOI
ScienceOn
|
13 |
Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom: further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992;267:7402-7405.
|
14 |
Nelson P, Poon T, Guan X, Schnabel C, Wintle M, Fineman M. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. Diabetes Technol Ther 2007;9:317-326.
DOI
ScienceOn
|
15 |
Chaisson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-2077.
DOI
ScienceOn
|
16 |
Riddle MC. Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin North Am 2005;34:77-98.
DOI
ScienceOn
|
17 |
Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes: HOE 901/3002 Study Group. Diabetes Care 2000;23:1130-1136.
DOI
ScienceOn
|